MDAT

MDAT
Systematic (IUPAC) name
	5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxol-7-amine
Clinical data
Pregnancy cat.	?
Legal status	Uncontrolled
Routes	Oral
Identifiers
CAS number	101625-35-8 freebase; 33446-21-8 hydrochloride salt
ATC code	None
PubChem	CID 36483
ChemSpider	33531
Chemical data
Formula	C11H13NO2
Mol. mass	191.223 g/mol
SMILES	eMolecules & PubChem

From Wikipedia, the free encyclopedia

Jump to: navigation, search

6,7-Methylenedioxy-2-aminotetralin (MDAT) is a drug developed in the 1990s by a team at Purdue University led by David E. Nichols.^[1] It appears to act as a serotonin releasing agent based on rodent drug discrimination assays comparing it to MDMA, in which it fully substitutes for, and additionally lacks any kind of serotonergic neurotoxicity.^[1] Hence, MDAT is considered likely to be a non-neurotoxic, putative entactogen in humans.

[edit] See also

^ ^a ^b Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM (February 1990). "Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry 33 (2): 703–10. doi:10.1021/jm00164a037. PMID 1967651.